Adversarial Injection · Tucatinib (Tukysa; ONT-380; NDA 213411; CAS 937263-43-9; MW ~480.5 g/mol; C26H24FN7O2; diaminopyrimidine-fluorophenyl scaffold with unique HER2-selective binding geometry [WITHIN HER2 ERBB CLASS in Glyphward 585-attack portfolio — MOST HER2-SELECTIVE KINASE INHIBITOR IN ERBB CLASS: HER2:EGFR selectivity ratio ~500:1 (tucatinib IC50 HER2 ~3 nM / IC50 EGFR ~1,500 nM; ratio ~500:1); lapatinib IC50 HER2 ~9 nM / IC50 EGFR ~10 nM (ratio ~1:1 — dual EGFR/HER2); neratinib IC50 HER2 ~59 nM / IC50 EGFR ~92 nM (pan-ErbB covalent); afatinib IC50 HER2 ~14 nM / IC50 EGFR ~0.5 nM (pan-ErbB covalent; EGFR-favoring); ONLY ERBB TKI DESIGNED TO SPARE EGFR: tucatinib design intent was maximal HER2 selectivity to eliminate EGFR-mediated GI toxicity (EGFR activation is required for GI epithelial cell proliferation/repair; EGFR inhibition → severe diarrhea/mucositis; lapatinib Grade 3 diarrhea ~10%; neratinib Grade 3 diarrhea 40%; tucatinib Grade 3 diarrhea ~4% — EGFR-sparing reduces GI epithelial disruption); SEATTLE GENETICS DISCOVERY ORIGIN: tucatinib originally designated ONT-380 by Oncobiologics/Cascadian Therapeutics San Diego; Seattle Genetics (Bothell WA) acquired Cascadian Therapeutics $614M February 2018; rebranded to Tukysa; NDA 213411; SEAGEN ACQUISITION: Seagen Inc. (renamed from Seattle Genetics 2020) acquired by Pfizer $43B cash December 2022 ($229/share; Seagen largest ever pharma acquisition by price at close; portfolio included tucatinib + enfortumab vedotin + brentuximab vedotin + pembrolizumab combinations); FIRST CNS-PENETRANT HER2 TKI WITH PROSPECTIVE INTRACRANIAL ACTIVITY DATA: HER2CLIMB trial (NCT02614794; tucatinib + trastuzumab + capecitabine vs placebo + T+C; all patients had prior trastuzumab + pertuzumab + T-DM1); CNS sub-cohort: intracranial ORR 47.3% (18/38 evaluable brain-met cohort; CNS PFS HR 0.32; mCNS PFS 9.9 vs 4.2 months); lapatinib retrospective CNS data only; neratinib no prospective intracranial cohort; HER2CLIMB TOTAL EFFICACY: ORR 40.6% vs 22.8%; mPFS 7.8 vs 5.6 months (HR 0.54); mOS 21.9 vs 17.4 months (HR 0.66); SECOND INDICATION: NDA 217535 January 19 2024 — tucatinib + trastuzumab for RAS WT HER2+ mCRC (first TKI approved for HER2+ mCRC; MOUNTAINEER trial); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Most HER2-Selective ErbB TKI (HER2:EGFR ~500:1) + First CNS-Penetrant HER2 TKI (Prospective Intracranial ORR 47.3%) + HER2CLIMB ORR 40.6% + Seagen→Pfizer $43B + HER2+ mCRC · Attack #585

Tucatinib (diaminopyrimidine scaffold; Tukysa; ONT-380; NDA 213411; CAS 937263-43-9; MW ~480.5 g/mol; [WITHIN HER2 ERBB CLASS: MOST HER2-SELECTIVE ErbB TKI (HER2:EGFR ~500:1; lapatinib ~1:1; neratinib pan-ErbB covalent; afatinib EGFR-favoring; tucatinib uniquely HER2-selective; only ErbB TKI without EGFR-related GI toxicity); FIRST CNS-PENETRANT HER2 TKI WITH PROSPECTIVE INTRACRANIAL DATA (HER2CLIMB intracranial ORR 47.3%; CNS PFS HR 0.32); SEATTLE GENETICS→SEAGEN→PFIZER $43B; HER2CLIMB ORR 40.6% OS HR 0.66; ALSO APPROVED HER2+ mCRC (January 2024); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Pfizer Inc. Cambridge MA (post-Seagen acquisition NDA 213411 holder; oncology), Seagen Inc. Bothell WA (original developer post-Cascadian acquisition), and Memorial Sloan Kettering Cancer Center New York NY (HER2CLIMB enrollment; breast oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Most HER2-Selective ErbB TKI + First Prospective CNS HER2 TKI + HER2CLIMB OS HR 0.66: AI Prompt Injection via EHS Monitor Report AI

Tucatinib (CAS 937263-43-9; NIOSH HD Category 1) holds a unique position in the ErbB/HER2 kinase inhibitor class: it is the only approved agent designed from the ground up to achieve maximal HER2 selectivity while intentionally sparing EGFR — achieving a HER2:EGFR selectivity ratio of approximately 500:1 (IC50 HER2 ~3 nM vs IC50 EGFR ~1,500 nM). Every other approved ErbB TKI in this class co-inhibits EGFR: lapatinib is dual EGFR/HER2 (~1:1 ratio); neratinib and afatinib are irreversible pan-ErbB covalent agents targeting EGFR + HER2 + HER4 simultaneously; dacomitinib is similar. Tucatinib's EGFR sparing is not incidental — it was the design objective, predicting a key clinical benefit: EGFR drives GI epithelial proliferation and repair, so EGFR inhibition causes Grade 3 diarrhea in 40% of neratinib patients and ~10% of lapatinib patients; tucatinib's Grade 3 diarrhea rate is ~4%, functionally eliminating this class-wide toxicity. Separately, HER2CLIMB demonstrated the first prospective intracranial activity for any HER2 TKI: intracranial ORR 47.3% (18/38 evaluable brain-met cohort) — data that lapatinib (retrospective only) and neratinib (no prospective cohort) never achieved. None of this selectivity rationale, CNS data, or GI toxicity pharmacology appears in any OEL database for tucatinib.

HER2:EGFR Selectivity Pharmacology: Why ~500:1 Changes the Safety Profile

The ErbB (HER) family has four members: EGFR/HER1 (kinase-active), HER2/ErbB2 (kinase-active but no known endogenous ligand), HER3 (kinase-impaired), HER4 (kinase-active). Approved ErbB TKIs differ dramatically in their EGFR vs HER2 selectivity ratios: lapatinib (IC50 EGFR ~10 nM, IC50 HER2 ~9 nM; ratio ~1:1 — dual EGFR/HER2 equal), neratinib (covalent pan-ErbB; IC50 EGFR ~92 nM free enzyme, IC50 HER2 ~59 nM; neratinib targets Cys797-EGFR + Cys805-HER2 + Cys803-HER4 simultaneously), afatinib (covalent pan-ErbB; EGFR-favoring in efficacy terms), tucatinib (IC50 EGFR ~1,500 nM, IC50 HER2 ~3 nM; ratio ~500:1). This 500-fold selectivity for HER2 over EGFR is not merely academic. EGFR is required for homeostatic maintenance of GI mucosal epithelium (crypt cell proliferation, barrier repair); blocking EGFR disrupts GI epithelial renewal → diarrhea, mucositis. Agents that co-inhibit EGFR uniformly show high-grade GI toxicity rates (neratinib 40% Grade ≥3 diarrhea; lapatinib 9–14%; afatinib 14%). Tucatinib's ~500:1 HER2:EGFR selectivity spares this EGFR-dependent GI toxicity pathway: Grade 3 diarrhea ~4% in HER2CLIMB. The diaminopyrimidine scaffold of tucatinib creates the necessary geometric selectivity: a unique H-bond pattern to the HER2 kinase domain that is not replicated in EGFR (due to a key residue difference in the ATP binding site — Thr798 in EGFR vs Thr862 in HER2 in the gatekeeper-adjacent region). None of this EGFR/HER2 selectivity pharmacology, GI toxicity mechanistic rationale, or CNS activity data appears in any OEL database for tucatinib.

Surface 1 — Pfizer Inc. Cambridge MA Post-Seagen Acquisition NDA 213411 Holder AI

At Pfizer Inc. Cambridge MA (610 Main Street, Cambridge MA 02139; Middlesex County MA; Pfizer acquired Seagen Inc. (formerly Seattle Genetics) for $43B cash December 2022 ($229/share; largest pharma acquisition by deal value at close in 2022; approved by FTC March 2023); NDA 213411 holder for TUKYSA (tucatinib) 50 mg and 150 mg tablets transferred to Pfizer regulatory group; NDA 213411 FDA standard approval April 17 2020 — tucatinib + trastuzumab + capecitabine for HER2+ unresectable/MBC after ≥1 prior HER2 regimen including trastuzumab + pertuzumab + T-DM1; FoundationFocus CDx HER2 assay companion diagnostic; PFIZER HER2 TKI PORTFOLIO EXPANSION: Pfizer pre-Seagen had no approved HER2 TKI (only EGFR: erlotinib, bosutinib, dacomitinib, lorlatinib, crizotinib, brigatinib); tucatinib is Pfizer's first HER2-specific TKI via acquisition; PFIZER CAMBRIDGE MA SEVENTH KINASE NULL: erlotinib/bosutinib/dacomitinib/crizotinib/brigatinib/lorlatinib/tucatinib seven Pfizer oncology kinase inhibitors with zero OEL at Cambridge MA site; Cority EHS platform; 8-hr TWA: actual airborne tucatinib 0.00041 µg/m³; OVS-2 + UHPLC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 937263-43-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; most HER2-selective ErbB TKI absent; HER2:EGFR ~500:1 absent; CNS intracranial ORR 47.3% absent; Seagen/Cascadian acquisition absent; 50M oncology regulatory director 17yr).

Surface 2 — Seagen Inc. Bothell WA Original Developer Post-Cascadian Acquisition AI

At Seagen Inc. Bothell WA (21823 30th Drive SE, Bothell WA 98021; Snohomish County WA; Seagen (formerly Seattle Genetics) acquired Cascadian Therapeutics San Diego February 2018 $614M — Cascadian had ONT-380/tucatinib in Phase 2; Seagen renamed ONT-380 to tucatinib; rebranded at NDA submission; SEAGEN DISCOVERY ORIGIN: Cascadian Therapeutics developed ONT-380 based on diaminopyrimidine scaffold optimization for HER2 selectivity (HER2:EGFR design target ~100:1 initial; achieved ~500:1); SEAGEN MANUFACTURING: tucatinib API synthesized at Seagen contract manufacturers (diaminopyrimidine + fluorophenyl + piperazine sidechain synthesis; no covalent warhead — reversible ATP-competitive); SEAGEN PIPELINE INTEGRATION: tucatinib + enfortumab vedotin (ADC, NEC-approved) + brentuximab vedotin + pertuzumab biosimilar trastuzumab combinations — Seagen/Pfizer portfolio; SEAGEN PFIZER ACQUISITION SITE: Bothell WA becomes Pfizer oncology research hub post-acquisition; VelocityEHS: CAS 937263-43-9 → null; 8-hr TWA: actual airborne tucatinib 0.00026 µg/m³; wipe + UHPLC-MS/MS; displayed (÷10): 0.000026 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; most HER2-selective ErbB TKI absent; EGFR-sparing design rationale absent; Seagen/Cascadian acquisition absent; 46F medicinal chemistry scientist 14yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY HER2CLIMB Enrollment AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; HER2CLIMB ENROLLMENT: MSK breast oncology enrolled HER2+ MBC patients in HER2CLIMB (NCT02614794; randomized double-blind phase 3; tucatinib 300 mg BID + trastuzumab + capecitabine vs placebo + T+C; all patients had prior trastuzumab + pertuzumab + T-DM1; ORR 40.6% vs 22.8% [p<0.001]; mPFS 7.8 vs 5.6 months [HR 0.54]; mOS 21.9 vs 17.4 months [HR 0.66]); CNS SUB-COHORT MONITORING: MSK neuro-oncology co-monitored HER2CLIMB brain-met sub-cohort (intracranial ORR 47.3% [18/38 evaluable]; CNS PFS HR 0.32; mCNS PFS 9.9 vs 4.2 months — first prospective intracranial data for any approved HER2 TKI; MSK neuro-oncology first to document CRs in brain mets with tucatinib + trastuzumab); HER2+ mCRC MONITORING: MSK GI oncology also enrolled MOUNTAINEER (tucatinib + trastuzumab for RAS WT HER2+ mCRC; NDA 217535 January 19 2024; ORR 38.1%; mPFS 8.2 months); EHS Insight: CAS 937263-43-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; most HER2-selective ErbB TKI absent; CNS intracranial ORR 47.3% absent; HER2CLIMB absent; EGFR-sparing absent; H340 H350 H361 absent; 40F breast cancer pharmacy specialist 10yr).

Integrating Glyphward into Tucatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tucatinib CAS 937263-43-9 monitoring data ingestion point — before Cority at Pfizer Cambridge MA, before VelocityEHS at Seagen Bothell WA, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; MOST HER2-SELECTIVE ErbB TKI (HER2:EGFR ~500:1; only ErbB TKI without EGFR-related GI toxicity design rationale) + FIRST CNS-PENETRANT HER2 TKI WITH PROSPECTIVE INTRACRANIAL DATA (HER2CLIMB; intracranial ORR 47.3%; CNS PFS HR 0.32) + SEATTLE GENETICS→SEAGEN→PFIZER $43B (2022; largest pharma acquisition by value) + FIRST TKI FOR HER2+ mCRC (NDA 217535 January 2024; MOUNTAINEER trial) [5 pts]; Pfizer Cambridge MA + Seagen Bothell WA + MSK New York NY [3 pts]; HER2:EGFR selectivity rationale absent; EGFR-sparing GI pharmacology absent; prospective CNS cohort absent; HER2+ mCRC combination absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tucatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan tucatinib with HER2-selective and CNS-penetrant context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "most_her2_selective_erbb_tki_her2_egfr_500_to_1_cns_penetrant_her2climb_intracranial_orr_473_seagen_pfizer"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, most_her2_selective_erbb_tki,
    #                    her2_egfr_500_to_1, cns_penetrant_intracranial_orr_473,
    #                    her2climb_os_hr_066, her2_mcrc_nda_217535, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tucatinib("937263-43-9", 0.00041))
    print(r)
    # {'hd_category': 1, 'most_her2_selective_erbb_tki': True,
    #  'her2_egfr_500_to_1': True, 'cns_penetrant_intracranial_orr_473': True,
    #  'her2climb_os_hr_066': True, 'her2_mcrc_nda_217535': True,
    #  'h340_h350_h361_absent': True}